Scotiabank Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price decreased by equities research analysts at Scotiabank from $74.00 to $71.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s price target points to a potential upside of 135.88% from the company’s previous close.

Several other analysts have also weighed in on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Agios Pharmaceuticals Trading Down 2.7 %

AGIO stock opened at $30.10 on Friday. The company’s 50-day moving average price is $29.81 and its 200 day moving average price is $37.80. Agios Pharmaceuticals has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a market cap of $1.74 billion, a P/E ratio of 2.65 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities research analysts expect that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

Insider Transactions at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm’s stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $1,499,000. Nordea Investment Management AB grew its holdings in Agios Pharmaceuticals by 3.6% in the fourth quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company’s stock valued at $7,191,000 after purchasing an additional 7,593 shares during the period. Contravisory Investment Management Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth approximately $222,000. Inspire Investing LLC raised its stake in Agios Pharmaceuticals by 34.2% during the fourth quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 3,156 shares during the period. Finally, KBC Group NV boosted its holdings in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.